Screening ionisable lipids with a gene-editor-sized RNA identified LC-1, an LNP component that retained potency as cargo ...

Incyte will share updated clinical single-cell data characterizing its calreticulin-targeted therapy for myeloproliferative ...

Researchers in Germany have identified a SOX9-responsive regulatory route to IRF6, a major orofacial-cleft risk gene, in ...

Wave Life Sciences has reached alignment with the US Food and Drug Administration on a registrational pathway for WVE-006, a GalNAc-conjugated RNA... Cargo-Sized Lipid Screen Extends Gene Editing ...

Ole Bock moderated two sessions at the Chinese Society of Cell & Gene Therapy Annual Meeting in Beijing, and CMN received the ...

Sofi-cel is an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy being developed for T-cell cancers. Allotera uses ...

CMN founder Jens-Ole Bock will moderate a panel discussion at CSGCT 2026 in Beijing on 20 September on the question that now defines the field: with the first in vivo CRISPR therapy under FDA priority ...

Delivering a CRISPR-Cas-derived adenine base editor as a short-lived protein-guide RNA complex enabled efficient PCSK9 editing while human embryos developed to blastocysts. By contrast, mRNA delivery ...

CMN Intelligence has released the CMN Clinical Trials Q2 2026 Global Report, based on data from the CRISPR Medicine News Global Clinical Trials ...

Base editing offers far more versatility than its name implies. The technique was initially developed to correct single-nucleotide variants by replacing one DNA base with another. However, researchers ...